NCT02920008 2024-08-28
Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia
Astex Pharmaceuticals, Inc.
Phase 3 Completed
Clinical Trials
8 trialsNCT01696032 2024-08-27
SGI-110
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT01752933 2024-08-27
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT02348489 2024-08-27
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT02907359 2024-08-27
Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs
Astex Pharmaceuticals, Inc.
Phase 3 Completed
NCT03603964 2024-08-27
Guadecitabine Extension Study
Astex Pharmaceuticals, Inc.
Phase 2 Terminated
NCT02293993 2021-03-05
Phase 1 Study of SGI-110 in Patients With Acute Myeloid Leukemia
Otsuka Pharmaceutical Co., Ltd.
Phase 1 Completed
NCT02892318 2020-03-13
A Study Evaluating the Safety and Pharmacology of Atezolizumab Administered in Combination With Immunomodulatory Agents in Participants With Acute Myeloid Leukemia (AML)
Hoffmann-La Roche
Phase 1 Completed